Eli Lilly
OncoDNA, Eli Lilly Partner on Thyroid Cancer Biomarker Testing
The companies are working together to offer next-generation sequencing-based molecular testing on thyroid cancer biopsies to clinicians in Italy.
Thermo Fisher Gets FDA OK for CDx Test to Guide Use of Lilly Drug in Lung, Thyroid Cancers
The NGS-based Oncomine Dx Target Test will help ID patients with advanced RET-driven lung and thyroid cancers who may be eligible for treatment with Eli Lilly's Retevmo.
Tempus, Children's Oncology Group Expand Genomic Testing Access for Pediatric Cancer Patients
Tempus' xT platform will be used to identify patients likely to match for a trial assessing the efficacy of genetically informed treatments in certain pediatric cancers.
Tempus, Lilly Ink Partnership to Offer No-Cost NGS for Advanced NSCLC Patients
Lilly will cover the cost of Tempus' broad-based sequencing tests for advanced non-small cell lung cancer patients to improve biomarker testing access.
In Brief This Week: Labcorp, Grail, AnPac Bio-Medical, CDC, Agilent Technologies, More
News items for the week of May 30, 2022.
Jun 18, 2020
Sep 24, 2014